Sourcing Exosomes in Wisconsin
Licensed Wisconsin practices order Kimera exosome material from ExaVeyra for topical aesthetic use, shipped frozen from Florida with a Certificate of Analysis and lot traceability on every vial. Wisconsin buyers need their own professional license and NPI; the wholesale distributor license is the supplier’s obligation, not the purchaser’s.
Wisconsin practices are living through a transition worth planning around: on 1 September 2026 the Board of Nursing began issuing advanced practice registered nurse licenses under 2025 Wisconsin Act 17, a law the state debated for the better part of a decade. The collaboration and independent practice rules it sets are new, and the board is still filling in detail by emergency rule.
At a glance
| Question | Answer |
|---|---|
| Does ExaVeyra ship to Wisconsin? | Yes. Shipped frozen from Florida, as we do to all 50 states |
| Cold-chain shipping from Florida | Overnight shipping; arrival can take 1 to 3 business days |
| State regenerative-medicine statute | None |
| Does that statute reach exosomes? | No. Its definition is written around cells; exosomes are acellular and governed federally |
| Physician delegation required to hand off medical acts | Yes |
| Who holds the licensure to ship into the state | The pharmacy partner and the tissue bank that ship, not the purchasing practice |
| What ExaVeyra supplies here | Kimera exosome material; compounded preparations available through the 503A pharmacy partner |
| Last reviewed | 16 October 2026 |
Ordering from Wisconsin
ExaVeyra ships to licensed practices in all 50 states, Wisconsin included. Licensure for shipping into the state is held by the entities that ship: our 503A pharmacy partner holds nonresident pharmacy licenses in 33 jurisdictions, including Puerto Rico, and exosome material ships from a registered tissue bank licensed to ship to all 50 states and Puerto Rico. Your practice orders against its own professional license and NPI and needs no wholesale permit to purchase.
What your practice provides
- An active Wisconsin professional license in good standing, verifiable through the DSPS credential search.
- A valid NPI, which ExaVeyra verifies at account setup.
- A signed professional-use acknowledgment on file for exosome material.
- A Wisconsin resale exemption certificate from the Department of Revenue if the practice is purchasing for resale rather than for use in its own operations.
How the state permits wholesale distribution
Wisconsin licenses wholesale distribution through the Pharmacy Examining Board within the Department of Safety and Professional Services. No person may engage in the wholesale distribution of a prescription drug in the state without a license for each facility from which prescription drugs are distributed, and the requirement reaches out-of-state facilities shipping in as well as in-state ones. Applicants post a $5,000 surety bond or irrevocable letter of credit, name a fingerprinted designated representative, and either schedule an approved inspection or hold NABP Drug Distributor Accreditation. The regime covers prescription drugs rather than devices, and the license sits with the distributor, not with the purchasing practice.
Wis. Stat. 450.071; Wis. Admin. Code ch. Phar · Wisconsin Pharmacy Examining Board, Department of Safety and Professional Services
Wisconsin regenerative-medicine law
Wisconsin has not enacted a statute specific to stem cell or regenerative therapies. Practice in this area is governed by the state's general medical practice and professional licensing rules, alongside federal law.
Wisconsin has no statute that authorizes, conditions, or requires disclosure for unapproved regenerative therapy, so federal law is the only layer that addresses it. Practice in this area is governed by the Medical Practice Act in chapter 448, the nursing statutes in chapter 441 as rewritten by 2025 Wisconsin Act 17, and the boards that administer them, alongside the FDA’s framework for human cells, tissues, and biological products.
How this applies to exosomes
Wisconsin has not enacted a stem cell authorization law like Florida, Texas, or Georgia, a disclosure law like California or Utah, or a documentation statute like Tennessee, and its 2025 and 2026 sessions legislated on who may practice, not on regenerative products. There is therefore no Wisconsin definition to read exosomes into or out of, and exosomes are acellular extracellular vesicles that no statute here addresses. Exosome products in Wisconsin are governed by federal law, under which no exosome product has been approved by the FDA for administration to humans. ExaVeyra supplies Kimera material for topical aesthetic use by licensed practitioners, with full COA and lot documentation.
Who can handle product in a Wisconsin practice
The thing to plan around in Wisconsin is the transition. The APRN licensure system took effect on 1 September 2026, the Board of Nursing is issuing licenses under emergency rules, and prior advanced practice nurse prescriber certificates convert to APRN licenses. A practice built on physician delegation keeps working as before; an APRN-led structure becomes possible once the double 3,840-hour threshold is met, with a medical director still needed where a procedure falls outside APRN scope or a payer requires one. Pain management using invasive techniques carries its own collaboration requirement even for independent APRNs outside hospital settings. All the professions here are administered by the Department of Safety and Professional Services, so license verification runs through a single credential search.
| Role | Scope under state law |
|---|---|
| MD / DO | Physicians licensed by the Medical Examining Board under chapter 448 may perform medical acts within their scope and are the source of any delegation to staff who do not hold independent authority. |
| NP / APRN | Since 1 September 2026, nurse practitioners are licensed as advanced practice registered nurses by the Board of Nursing under 2025 Wisconsin Act 17. An APRN practices in collaboration with a physician or dentist unless qualified for independent practice, which requires 3,840 hours of professional nursing in a clinical setting over at least 24 months plus 3,840 hours of APRN practice in the recognized role with a physician or dentist immediately available for consultation, also over at least 24 months. An independently practicing APRN must carry malpractice coverage and participate in the Injured Patients and Families Compensation Fund. |
| PA | Physician assistants practice in collaboration with, rather than under the supervision of, a physician, under 2021 Wisconsin Act 23, with the collaboration arrangement set at the practice level and licensure through the Physician Assistant Affiliated Credentialing Board in chapter 448. |
| RN | Registered nurses perform delegated treatments within their scope and under an order from a provider with authority to issue one. Act 17 also lets a licensed APRN delegate a task or order to another clinically trained health care worker, so RN delegation in an APRN-led practice now has a statutory basis of its own. |
Good faith examination
Wisconsin expects a patient evaluation by a provider with authority to conduct it, and an order, before a delegated treatment is administered. Where an APRN qualifies for independent practice under Act 17, that provider can be the APRN; the act also obliges an APRN to consult, collaborate, or refer when a patient’s needs exceed the APRN’s expertise. Confirm current expectations with the Medical Examining Board and the Board of Nursing, since the implementing rules are new and still being filled in.
Ownership and clinic licensing
Wisconsin does not codify a corporate practice of medicine prohibition the way Texas, New York, or New Jersey do, and professional entities together with management services arrangements are the usual structures. Because the position rests on entity law and board regulation rather than a bright-line statute, published summaries disagree at the margins, so treat ownership structure as a question for Wisconsin counsel and the Medical Examining Board rather than one a guide should answer with a percentage.
Cold chain into Wisconsin
Shipments leave Florida frozen under validated temperature monitoring. A package in transit over a weekend waits in the carrier network, so practices in Wisconsin order around weekend and holiday closures.
| Metro | County | Notes |
|---|---|---|
| Milwaukee | Milwaukee | Largest Wisconsin market, with the deepest aesthetic and clinical coverage. |
| Madison | Dane | Capital and university market with academic medicine and a growing wellness segment. |
| Brookfield | Waukesha | Western suburban corridor with a concentrated med spa presence. |
| Mequon | Ozaukee | North Shore market served alongside Milwaukee. |
| Green Bay | Brown | Northeast Wisconsin hub with orthopedics and sports medicine demand. |
| Appleton | Outagamie | Fox Valley market with a steady aesthetic base. |
- Wisconsin orders of fifteen or more cold-chain units ship free nationwide; see the volume program for current thresholds.
- The lot-specific Certificate of Analysis is provided on request for every lot; the manufacturer’s handling instructions accompany each order, so store to the labeled conditions on arrival.
Wholesale exosome supply by city in Wisconsin
Each city page covers local receiving conditions, delivery disruptions and business license rules for Wisconsin practices in that area.
Practice types we supply in Wisconsin
Wisconsin licensing and verification
Wisconsin Medical Examining Board
Licenses physicians under chapter 448; the PA Affiliated Credentialing Board is attached to it.
Wisconsin Board of Nursing
Began issuing APRN licenses on 1 September 2026 under 2025 Act 17.
Wisconsin Pharmacy Examining Board
Issues the per-facility wholesale distributor of prescription drugs license.
Wisconsin Department of Revenue
Sales and use tax registration and resale exemption certificates.
Wisconsin sourcing questions
- Does Wisconsin have a stem cell law?
- No. Wisconsin has no stem cell authorization law, disclosure law, or documentation statute, and its recent sessions legislated on practitioner licensure rather than regenerative products. Exosome products in Wisconsin are governed by federal law, under which no exosome product is FDA-approved for administration to humans.
- Are exosomes FDA approved?
- No exosome product has been approved by the FDA for administration to humans, in Wisconsin or anywhere else, and the FDA has issued a public safety notification saying exactly that. ExaVeyra supplies Kimera exosome material for topical aesthetic use by licensed practitioners, with a Certificate of Analysis and lot documentation on every vial.
- What did 2025 Wisconsin Act 17 change for nurse practitioners?
- It created APRN licensure, effective 1 September 2026, after vetoes of earlier versions in 2022 and 2024. An APRN practices in collaboration with a physician or dentist unless qualified for independent practice, which takes 3,840 hours of clinical nursing over at least 24 months plus 3,840 hours of APRN practice with a physician or dentist immediately available, also over at least 24 months. Independent APRNs must participate in the Injured Patients and Families Compensation Fund, and invasive pain management keeps its own collaboration requirement outside hospital settings.
- Do Wisconsin physician assistants still need a supervising physician?
- Not in the old sense. 2021 Wisconsin Act 23 moved the relationship from supervision to collaboration, removed the fixed physician-to-PA ratio, and created a Physician Assistant Affiliated Credentialing Board attached to the Medical Examining Board. The collaboration arrangement is set at the practice level.
- Does my Wisconsin clinic need a wholesale distributor license to buy exosomes?
- No. The wholesale distributor of prescription drugs license under Wis. Stat. 450.071 is held per facility by the distributor shipping into Wisconsin, not by the practice buying. Your practice orders against its own professional license and NPI. Licensure for shipping into the state is held by the entities that ship: our 503A pharmacy partner for compounded preparations, and a registered tissue bank licensed to ship to all 50 states and Puerto Rico for exosome material.
- How long does cold-chain shipping take to Wisconsin?
- Ships from Florida by overnight shipping, and arrival can take one to three business days. All exosome shipments travel cold-chain with validated temperature monitoring. A shipment in transit over a weekend waits in the carrier network, so a practice that will be closed orders around the closure.
Sources
Last reviewed 16 October 2026 by ExaVeyra Sciences editorial team. Every claim above links to a primary source.
- 2025 Wisconsin Act 17, advanced practice registered nurses (accessed 16 October 2026)
- Wisconsin Legislative Council act memo, 2025 Act 17 (accessed 16 October 2026)
- Wis. Stat. 450.071, wholesale distributors; licensure (accessed 16 October 2026)
- Wisconsin DSPS, wholesale distributor of prescription drugs (accessed 16 October 2026)
- Wisconsin Board of Nursing (accessed 16 October 2026)
- Wisconsin Department of Revenue (accessed 16 October 2026)
- FDA Public Safety Notification on Exosome Products (accessed 16 October 2026)
Scientific literature
Peer-reviewed references, each with its study design and, for human studies, the number of participants, so a reader can judge the weight of a citation without opening it. None is a claim about any product.
- Welsh JA, Goberdhan DCI, O’Driscoll L, et al. Minimal information for studies of extracellular vesicles (MISEV2023): From basic to advanced approaches. Journal of Extracellular Vesicles, 2024. doi:10.1002/jev2.12404 PMID:38326288Clinical guidelinesupports: The current international reporting standard for extracellular vesicle characterization, the framework behind the identity and purity parameters a Wisconsin practice should expect on an exosome Certificate of Analysis.
- Witwer KW, Van Balkom BWM, Bruno S, et al. Defining mesenchymal stromal cell (MSC)-derived small extracellular vesicles for therapeutic applications. Journal of Extracellular Vesicles, 2019. doi:10.1080/20013078.2019.1609206 PMID:31069028Consensus statementsupports: The ISEV position paper on documenting MSC-derived small EV preparations, which supports this page’s point that in a state with no regenerative statute, supplier documentation is the quality layer that exists.
- Yáñez-Mó M, Siljander PR, Andreu Z, et al. Biological properties of extracellular vesicles and their physiological functions. Journal of Extracellular Vesicles, 2015. doi:10.3402/jev.v4.27066 PMID:25979354Narrative reviewsupports: The foundational review of extracellular vesicle biology, supporting this page’s distinction between acellular vesicles and the cells and tissues that other states’ statutes address.
These statements have not been evaluated by the FDA. This product is not intended to diagnose, treat, cure, or prevent any disease. There are no FDA-approved exosome products. Biomolecular signaling vesicle products distributed by ExaVeyra Sciences are supplied for topical aesthetic use by licensed practitioners and for laboratory and IND-authorized clinical research, and are not tissue products as defined by FDA guidelines.